Impact du polymorphisme des récepteurs FcγRIIA et FcγRIIIA couplé à la fonctionnalité des cellules Natural Killer sur la réponse clinique des patients atteints de carcinome épidermoïde des voies aéro-digestives supérieures, traités par Cetuximab

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  2015-07-10

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Évaluation de la fonction des cellules natural killer chez les patients présentant un carcinome épidermoïde des voies aérodigestives supérieures en situation palliative, devant recevoir du cetuximab : une étude préliminaire

  2013cited by this paper
• A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  2012cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Estimates of cancer incidence and mortality in Europe in 2008.

  2010cited by this paper
• Signalisation cellulaire et cancer

  2010cited by this paper
• Growth Suppression of Human Hepatocellular Carcinoma Xenografts by a Monoclonal Antibody CH12 Directed to Epidermal Growth Factor Receptor Variant III*

  2010cited by this paper
• HPV-associated head and neck cancer: a virus-related cancer epidemic.

  2010cited by this paper
• Mécanismes de résistance au cetuximab et influence des associations de traitement dans des lignées cellulaires de cancers de voies aérodigestives supérieures

  2010cited by this paper
• Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation

  2009cited by this paper
• Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

  2009cited by this paper
• The structure, genetic polymorphisms, expression and biological functions of complement receptor type 1 (CR1/CD35)

  2009cited by this paper
• Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development.

  2009cited by this paper
• Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck

  2008cited by this paper
• Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies.

  2008cited by this paper
• The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility

  2008cited by this paper
• Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

  2008cited by this paper
• Molecular Targeting and Treatment of Composite EGFR and EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibodies

  2008cited by this paper
• Binding of Rituximab, Trastuzumab, Cetuximab, or mAb T101 to Cancer Cells Promotes Trogocytosis Mediated by THP-1 Cells and Monocytes1

  2008cited by this paper
• Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.

  2007cited by this paper
• Cancers des voies aéro-digestives supérieures

  2007cited by this paper
• Mechanisms for oncogenic activation of the epidermal growth factor receptor.

  2007cited by this paper
• Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.

  2007cited by this paper
• Protein kinase C and other diacylglycerol effectors in cancer

  2007cited by this paper
• Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.

  2007cited by this paper
• FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

  2007cited by this paper
• The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions

  2006cited by this paper
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

  2006cited by this paper
• Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

  2006cited by this paper
• Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.

  2006cited by this paper
• The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

  2006cited by this paper
• Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma.

  2006cited by this paper
• Tissue microarray analysis of EGFR and HER2 oncogene copy number alterations in squamous cell carcinoma of the larynx

  2005cited by this paper
• Retracted: Frequent genetic and biochemical alterations of the PI 3‐K/AKT/PTEN pathway in head and neck squamous cell carcinoma

  2005cited by this paper
• Radiation-induced Epidermal Growth Factor Receptor Nuclear Import Is Linked to Activation of DNA-dependent Protein Kinase*

  2005cited by this paper
• A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy.

  2005cited by this paper
• Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.

  2005cited by this paper
• Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis

  2005cited by this paper
• Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy

  2004cited by this paper
• Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy.

  2004cited by this paper
• The discovery of receptor tyrosine kinases: targets for cancer therapy

  2004cited by this paper
• Mechanisms of resistance to erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells

  2004cited by this paper
• ERBB receptor tyrosine kinases and cellular radiation responses

  2003cited by this paper
• Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.

  2003cited by this paper
• Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

  2002cited by this paper
• Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

  2002cited by this paper
• Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.

  2001cited by this paper
• Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.

  2001cited by this paper
• Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers

  1998cited by this paper
• Protein expression of cancer associated genes: biopsy material compared to resection material in laryngeal cancer.

  1998cited by this paper
• Prognostic significance of natural killer cell activity in patients with laryngeal carcinoma.

  1998cited by this paper
• Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors.

  1998cited by this paper
• Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation

  1997cited by this paper
• ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

  1997cited by this paper
• Epidermal growth factor-related peptides and their receptors in human malignancies.

  1995cited by this paper
• Molecular cloning of mouse epiregulin, a novel epidermal growth factor‐related protein, expressed in the early stage of development

  1995cited by this paper
• Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.

  1995cited by this paper
• ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms.

  1994cited by this paper
• Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor

  1994cited by this paper
• H-ras oncogene mutation and human papillomavirus infection in oral carcinomas.

  1994cited by this paper
• Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis.

  1994cited by this paper
• The incidence of p53 mutations increases with progression of head and neck cancer.

  1993cited by this paper
• Binding of monomeric human IgG defines an expression polymorphism of Fc gamma RIII on large granular lymphocyte/natural killer cells.

  1993cited by this paper
• Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma

  1993cited by this paper
• The physiology of transforming growth factor-alpha.

  1992cited by this paper
• A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding.

  1991cited by this paper
• The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity

  1990cited by this paper
• Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo.

  1987cited by this paper
• Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

  1984cited by this paper
• Lymphocyte Mediated Cytotoxicity in Vitro. Induction and Inhibition by Humoral Antibody and Nature of Effector Cells

  1972cited by this paper
• Epidermal growth factor

  1972cited by this paper
• Open Access the Proinflammatory Cytokines Il-2, Il-15 and Il-21 Modulate the Repertoire of Mature Human Natural Killer Cell Receptors

  year unknowncited by this paper
• Biologics: Targets & Therapy

  year unknowncited by this paper

• No citing papers are available for this paper.